Protagonist Therapeutics Inc (PTGX) valuation
Protagonist Therapeutics P/E ratio history
Protagonist Therapeutics trades at 140.6 times its earnings over the last twelve months and 61.9 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $87.34 | -$2.05 | n/m |
| Dec 31, 2024 | $38.60 | $4.23 | 9.1 |
| Dec 31, 2023 | $22.93 | -$1.39 | n/m |
| Dec 31, 2022 | $10.91 | -$2.60 | n/m |
| Dec 31, 2021 | $34.20 | -$2.71 | n/m |
| Dec 31, 2020 | $20.16 | -$1.99 | n/m |
| Dec 31, 2019 | $7.05 | -$2.99 | n/m |
| Dec 31, 2018 | $6.73 | -$1.74 | n/m |
| Dec 31, 2017 | $20.80 | -$2.10 | n/m |
| Dec 31, 2016 | $21.99 | — | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Protagonist Therapeutics valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Protagonist TherapeuticsPTGX | $9.32B | 140.6 | 61.9 | 33.0 |
| Tg TherapeuticsTGTX | $9.37B | 22.3 | 33.5 | 11.7 |
| Twist BioscienceTWST | $9.51B | — | — | 22.0 |
| Henry ScheinHSIC | $9.67B | 24.8 | 14.9 | 0.7 |
| VaxcytePCVX | $8.96B | — | — | — |
| 10X GenomicsTXG | $8.90B | — | — | 14.4 |
| Krystal BiotechKRYS | $9.80B | 41.7 | 40.2 | 22.2 |
| Madrigal PharmaceuticalsMDGL | $9.92B | — | — | 7.7 |
| Corcept TherapeuticsCORT | $8.71B | 193.1 | 25.7 | 10.5 |
| Peer median | 33.2 | 29.6 | 11.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PTGX financials · PTGX returns
No forecast, no recommendation. This page describes Protagonist Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.